This phase II trial – to start in November 2008 – is not yet open for recruitment. Target enrollment is 628 migraine patients (with or without aura) who have had 1 to 8 severe attacks per month the 2 months prior to study. Locations are not yet listed.
Official Title: “A study to test the safety and effectiveness of MK0974 co-administered with ibuprofen or acetaminophen in patients with migraines with or without aura” – ClinicalTrials.gov ID# NCT00758836.
The study will compare treatment with:
• Merck experimental drug telcagepant (MK0974) only;
• MK0974 plus ibuprofen,
• MK0974 plus acetaminophen,
• And placebo.
This study follows a large phase III effectiveness & safey study of MK0907 (see the ClinicalTrialsToday.com report on that study’s findings – “Migraine Study Shows Merck’s Telcagepant Promising”).
For more information about the new study, inclusion and exclusion criteria, and a toll free contact number for questions, see the ClinicalTrials.gov listing for trial # NCT00758836